SEC Tracker
Get the app
GRML · XBRL financial data

Greenland Mines financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (GRML's year ends in late December)

In thousands of dollarsDec 31, 2022†Dec 31, 2023†Dec 31, 2024Dec 31, 2025
Research and development—00634
General and administrative5341,2251293,076
Total operating expenses—6315,5407,146
Operating income (loss)(657)(1,301)(5,540)(7,146)
Interest income1,2813,364——
Interest expense—763572,314
Other income (expense)—0(252)115
Income tax expense (benefit)243691——
Net income (loss)1,2331,346(6,150)(10,552)
Earnings per share, basic USD per share—(0.05)(0.32)(0.22)
Earnings per share, diluted USD per share—(0.05)(0.32)(0.22)
Weighted average shares, basic thousands of shares—15,13019,24748,490
Weighted average shares, diluted thousands of shares—15,13019,24748,490
  • † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 16x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (GRML's year ends in late December)

In thousands of dollarsDec 31, 2022†Dec 31, 2023†Dec 31, 2024Dec 31, 2025
Cash and cash equivalents341173647,177
Total current assets4402001587,294
Total assets118,24719,4562,4579,593
Accounts payable—1516445
Accrued liabilities14039791232
Total current liabilities5062,3131,24877
Total deposits—35——
Total liabilities4,9298,2421,272130
Accumulated deficit(4,045)(7,351)(10,563)(21,114)
Total stockholders' equity(4,045)(7,351)1,1859,463
Total liabilities and equity118,24719,4562,4579,593
Common shares outstanding (cover page) thousands of shares8,8021,76028,511121,239
  • † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 16x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (GRML's year ends in late December)

In thousands of dollarsDec 31, 2022†Dec 31, 2023†Dec 31, 2024Dec 31, 2025
Net income (loss)1,2331,346(6,150)(10,552)
Stock-based compensation——2,6501,565
Net cash from operating activities(493)(1,263)(2,947)(5,889)
Net cash from investing activities(116,150)101,914(123)—
Proceeds from issuing common stock25100—1,113
Proceeds from issuing equity—60,000——
Net cash from financing activities116,979(100,820)3,13113,002
Net change in cash336———
  • † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 16x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Greenland Mines9,300not reported(6,854)*158.9M1.4 quarters 10-QJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
Sutro Biopharma54,3359,839(38,290)*16.6M4.3 quarters 10-QJun 30, 2026
PDS Biotechnology5,596not reported(2,793)*56.0M2.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.